Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS2 | Q07890 | 1/20 | 0.33 |
| ▸ | NQO1 | P15559 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27796512 | 0.85 | SOS2 (0.32) | SOS2NQO1 | |
| SCHEMBL12377890 | 0.81 | ALDH1A1 (0.35) | SOS2NQO1 | |
| SCHEMBL5099769 | 0.78 | SOS2 (0.34) | SOS2NQO1CTSB | |
| SCHEMBL836627 | 0.78 | SOS2 (0.34) | SOS2NQO1CTSB | |
| SCHEMBL11916709 | 0.74 | SOS2 (0.36) | SOS2NQO1 | |
| SCHEMBL844505 | 0.73 | KMT2A (0.31) | — | |
| SCHEMBL7846050 | 0.73 | SOS2 (0.38) | SOS2NQO1 | |
| SCHEMBL25268051 | 0.69 | KHK (0.36) | SOS2NQO1 | |
| SCHEMBL16372364 | 0.69 | SOS2 (0.48) | SOS2NQO1CTSB | |
| SCHEMBL2291603 | 0.69 | ALDH1A1 (0.44) | SOS2NQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2163554-B1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-7998954-B2 | Pyrimidodiazepinone derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-2163554-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2010-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KCNJ1, KCNJ11, ADRA1D | SOS2 2403/4885NQO1 959/4885CTSB 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.